M. Macpherson

585 total citations
21 papers, 454 citations indexed

About

M. Macpherson is a scholar working on Molecular Biology, Pharmacology and Genetics. According to data from OpenAlex, M. Macpherson has authored 21 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Pharmacology and 4 papers in Genetics. Recurrent topics in M. Macpherson's work include Antibiotics Pharmacokinetics and Efficacy (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Antibiotic Resistance in Bacteria (4 papers). M. Macpherson is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Antibiotic Resistance in Bacteria (4 papers). M. Macpherson collaborates with scholars based in United Kingdom, United States and Belgium. M. Macpherson's co-authors include Shampa Das, James G. Wright, Paul Newell, Todd Riccobene, Glen Clack, Neil J. Gallagher, Elizabeth B. Lamont, R.A. Seaton, Timothy J. Carrothers and Jeremy Hing and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Antimicrobial Agents and Chemotherapy.

In The Last Decade

M. Macpherson

20 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Macpherson United Kingdom 12 173 136 129 113 108 21 454
M. Kinzig‐Schippers Germany 9 200 1.2× 120 0.9× 89 0.7× 89 0.8× 39 0.4× 12 370
Tattersall Mh Australia 7 119 0.7× 69 0.5× 306 2.4× 88 0.8× 68 0.6× 18 484
G. Wesley White United States 12 102 0.6× 74 0.5× 140 1.1× 53 0.5× 89 0.8× 19 569
M. Calvo Spain 5 39 0.2× 92 0.7× 191 1.5× 52 0.5× 60 0.6× 5 349
Karen Cheng United Kingdom 9 149 0.9× 187 1.4× 267 2.1× 92 0.8× 98 0.9× 11 634
Nastya Kassir United States 13 82 0.5× 19 0.1× 54 0.4× 72 0.6× 69 0.6× 46 400
Perry S. Sawyer United States 4 70 0.4× 49 0.4× 128 1.0× 50 0.4× 53 0.5× 5 328
Motoshi Kawahara Japan 13 33 0.2× 48 0.4× 85 0.7× 55 0.5× 299 2.8× 38 564
R. Livingston United States 7 126 0.7× 57 0.4× 342 2.7× 61 0.5× 32 0.3× 12 789

Countries citing papers authored by M. Macpherson

Since Specialization
Citations

This map shows the geographic impact of M. Macpherson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Macpherson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Macpherson more than expected).

Fields of papers citing papers by M. Macpherson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Macpherson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Macpherson. The network helps show where M. Macpherson may publish in the future.

Co-authorship network of co-authors of M. Macpherson

This figure shows the co-authorship network connecting the top 25 collaborators of M. Macpherson. A scholar is included among the top collaborators of M. Macpherson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Macpherson. M. Macpherson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Das, Shampa, Todd Riccobene, Timothy J. Carrothers, et al.. (2024). Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation. European Journal of Clinical Pharmacology. 80(4). 529–543. 11 indexed citations
2.
Chanteux, Hugues, M. Macpherson, Christian Otoul, et al.. (2024). Overview of preclinical and clinical studies investigating pharmacokinetics and drug–drug interactions of padsevonil. Expert Opinion on Drug Metabolism & Toxicology. 20(8). 841–855.
3.
Otoul, Christian, M. Macpherson, Mark Watling, et al.. (2023). Clinical Bridging Studies and Modeling Approach for Implementation of a Patient Centric Sampling Technique in Padsevonil Clinical Development. The AAPS Journal. 26(1). 1–1. 4 indexed citations
4.
Rademacher, Michael, Manuel Toledo, Wim Van Paesschen, et al.. (2022). Efficacy and safety of adjunctive padsevonil in adults with drug‐resistant focal epilepsy: Results from two double‐blind, randomized, placebo‐controlled trials. Epilepsia Open. 7(4). 758–770. 18 indexed citations
5.
6.
Wright, James G., et al.. (2018). Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers. Drugs in R&D. 18(3). 221–230. 38 indexed citations
7.
Nichols, Wright W., Gregory G. Stone, Paul Newell, et al.. (2018). Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 62(11). 28 indexed citations
8.
Li, Jianguo, Mark Lovern, Michelle Green, et al.. (2018). Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. Clinical and Translational Science. 12(2). 151–163. 77 indexed citations
9.
Macpherson, M., Bengt Hamrén, Marjet J.A.M. Braamskamp, et al.. (2015). Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia. European Journal of Clinical Pharmacology. 72(1). 19–27. 7 indexed citations
10.
André, Fabrice, Malcolm Ranson, Emma Dean, et al.. (2013). Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .. Cancer Research. 73(8_Supplement). LB–145. 34 indexed citations
11.
André, Fabrice, Malcolm Ranson, Emma Dean, et al.. (2013). Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. Research Explorer (The University of Manchester). 16 indexed citations
12.
Horák, Jiří, Jeff White, Adrian L. Harris, et al.. (2011). The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology. 68(6). 1485–1495. 25 indexed citations
13.
Pritchard, Kathleen I., Janusz Rolski, Zsuzsanna Pápai, et al.. (2010). Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Research and Treatment. 123(2). 453–461. 70 indexed citations
14.
Lamont, Elizabeth B., et al.. (2009). Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. Journal of Antimicrobial Chemotherapy. 64(1). 181–187. 42 indexed citations
15.
Pritchard, Kathleen I., Janusz Rolski, Zsolt Pápai, et al.. (2009). A Phase II Study (FINDER 2) Comparing Three Dosing Regimens of Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.. Cancer Research. 69(24_Supplement). 4095–4095. 1 indexed citations
16.
Cantarini, Mireille, et al.. (2005). A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers. Cancer Chemotherapy and Pharmacology. 56(6). 557–562. 8 indexed citations
17.
Gallagher, Neil J., et al.. (2005). A phase I multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, orally available, dual-specific Src-Abl kinase inhibitor. 65. 935–935. 9 indexed citations
18.
Eastell, Richard, et al.. (2005). The effect of AZD0530, a highly selective, orally available Src/Abl kinase inhibitor, on biomarkers of bone resorption in healthy males. Journal of Clinical Oncology. 23(16_suppl). 3041–3041. 18 indexed citations
19.
McCormack, P. D., M. Macpherson, David M. Wilson, et al.. (2004). Pharmacokinetic characterization of the novel oral prenyl transferase inhibitor AZD3409: The first analysis in healthy male volunteers. Journal of Clinical Oncology. 22(14_suppl). 3172–3172. 3 indexed citations
20.
McCormack, P. D., et al.. (2004). Pharmacokinetic characterization of the novel oral prenyl transferase inhibitor AZD3409: The first analysis in healthy male volunteers. Journal of Clinical Oncology. 22(14_suppl). 3172–3172. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Kinzig‐Schippers Breakdown of academic impact, for papers by Tattersall Mh Breakdown of academic impact, for papers by G. Wesley White Breakdown of academic impact, for papers by M. Calvo Breakdown of academic impact, for papers by Karen Cheng Breakdown of academic impact, for papers by Nastya Kassir Breakdown of academic impact, for papers by Perry S. Sawyer Breakdown of academic impact, for papers by Motoshi Kawahara Breakdown of academic impact, for papers by R. Livingston
Rankless by CCL
2026